Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

020 8247 3351

49 Parkside, London, SW19 5NB
United Kingdom

New Icon Cancer Centre proposed at AMT Headingley to improve access to care across Leeds and Yorkshire

Icon Cancer Centre UK (Icon) has announced its intent to develop a new highly advanced cancer centre in Leeds, proposed as part of a broader health initiative at AMT Headingley Stadium. Designed to respond to growing community need, the proposed centre reinforces Icon’s long-term commitment to delivering accessible, locally led care for people living with cancer across the region.

In Leeds alone, around 27,000 people are currently living with or beyond cancer, with more than 4,100 new diagnoses each year1. The city has the highest cancer incidence rate in Yorkshire, reflecting its population size, ageing demographics and need for local healthcare.

Meeting rising cancer demand across Leeds and Yorkshire
Across the UK, one in two people will be diagnosed with cancer, and around half of all cancer patients are expected to require radiotherapy as part of their treatment2. Yet access remains a challenge, with many patients travelling long distances for daily appointments. National data shows that more than one in five people live over 45 minutes’ drive from a radiotherapy centre, rising significantly for those relying on public transport2.

Leeds is a major regional health hub, supporting patients from across Yorkshire, where someone is diagnosed with cancer every 17 minutes3. While survival outcomes continue to improve, with around 60% of cancers now diagnosed at an early stage nationally – demand for timely, accessible treatment remains high4.

Integrated care within historic AMT Headingley Stadium
The proposed Icon Cancer Centre would form part of a wider health offering at AMT Headingley Stadium, integrating cancer care alongside existing community health, wellbeing and sporting initiatives already delivered at the site.

Icon Group CEO, Mark Middleton OAM said the proposal aligns with Icon’s mission to deliver world‑class cancer care through strong, locally grounded partnerships.

“At Icon, our purpose is to improve access to lifesaving cancer care and to do so in a way that genuinely supports people and communities,” Mark said.

“Being part of the AMT Headingley health initiative allows us to embed cancer care within a broader ecosystem of health, wellbeing and community support — as part of the fabric of Leeds. This reflects Icon’s strong international track record of partnering locally to improve timely access to world‑class care.”

CEO Icon Europe, Aldo Rolfo, said the proposal marks a continued investment in the UK.

“This proposal will be a real win for Leeds and the Yorkshire community,” said Aldo.

“Building on the experience and success of Icon Cancer Centre London and our partnerships with leading national providers, we are bringing the same high standard of care and strengthening healthcare capacity in areas of need for the long term.”

Icon confirmed the centre will house the most advanced radiotherapy technology available – the first-of-its-kind to be implemented in the north of England and only the second in the UK, with the other at Icon Cancer Centre in London.

Community leaders back local health investment
Icon is working closely with a number of local partners as plans progress, including AMT Headingley Stadium, Leeds Rhinos and Headingley Cricket, Leeds City Council, and community leaders with deep local insight.

To support its engagement in Leeds and across the UK, Icon has appointed Dame Linda Pollard as Strategic Advisor. Dame Linda brings extensive experience and knowledge in the city’s health landscape, having previously served as Chair of Leeds Hospitals NHS Trust.

“Having been a healthcare decision-maker in Leeds for many years, I know how strong and proud this community is and how important access to timely cancer care is for local people,” Dame Linda Pollard said.

“I’m personally very excited to be part of this announcement. Developments like this, when they are grounded in partnership and shaped by local understanding, can make a real difference for patients and families.

“I’m pleased to be supporting Icon and Leeds Rhinos who both show a genuine commitment to improving healthcare for the people of Leeds.”

Paul Caddick MBE, Chairman of Caddick Group and owner of Leeds Rhinos and AMT Headingley Stadium, said the new health initiative builds on the organisation’s longstanding commitment to community wellbeing.

“AMT Headingley has always been about more than sport. Through the Leeds Rhinos Foundation and our wider work, we already support physical and mental health, inclusion and community resilience across Leeds,” Paul said.

“Creating a space for health initiatives that includes cancer care is a natural extension of that commitment and reflects what this site means to the community.”

Councillor James Lewis, leader of Leeds City Council said: “As a global top three HealthTech hub leading the Government’s flagship health mission, Leeds offers one of the UK’s most interconnected ecosystems. We really welcome the proposals from Icon and know their expertise and innovation will strengthen the sector in the city.”

The announcement coincides with a senior visit to Leeds, where Icon leadership and consortium partners across Leeds and AMT Headingley Stadium formally signed an agreement to progress the proposed health initiative.

Further details about the proposed centre will be shared as planning and engagement continue.

References

1 Leeds Cancer Programme. Transforming Cancer Care Together.

2 Radiotherapy UK (2024) – Equity of Access to Cancer Treatment. National analysis of radiotherapy need, access and travel times across the UK.

3 Yorkshire Cancer Research – The White Rose cancer Report. Regional cancer burden and incidence across Yorkshire.

4 NHS Digital. National Disease Registration Service (NDRS): Cancer incidence, prevalence and stage at diagnosis data for England.